Pneumocystis jirovecii infection

Miller, R.; Huang, L.
September 2004
Thorax;Sep2004, Vol. 59 Issue 9, p731
Academic Journal
The article focuses on the effects of the organism pneumocystis on individuals and mammals with immune disorders. It highlights on the development of severe pneumonia through pneumocystis in those people whose immune systems have been damaged by HIV, transplantation, malignancy, connective tissue disease, and their follow-up treatment. Earlier thought to be a species of protozoa, pneumocystis has been found out to be a fungus, to be genetically diverse, host species specific, transmissible from animal to animal, to colonize people with minor degrees of immunosupression, and to cause clinical disease by new infection in addition to latent childhood acquired infection.


Related Articles

  • Prospective cohort study showing changes in the monthly incidence of Pneumocystis carinii pneumonia. Lubis, N.; Baylis, D.; Short, A.; Stebbing, J.; Teague, A.; Portsmouth, S.; Bower, M.; Nelson, M.; Gazzard, B. // Postgraduate Medical Journal;Mar2003, Vol. 79 Issue 929, p164 

    Presents a prospective cohort study showing changes in the monthly incidence of Pneumocystis carinii pneumonia, a serious opportunistic condition in HIV-infected individuals. Association between seasonal changes in the climate and individual susceptibility to infection; Influence of climatic...

  • Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy. Kirk, Ole; Riess, Peter; Uberti-Foppa, Caterina; Bickel, Markus; Gerstoft, Jan; Pradler, Christian; Wit, Ferdinand W.; Ledergerber, Bruno; Lundgren, Jens D.; Furrer, Hansjakob // Annals of Internal Medicine;8/20/2002, Vol. 137 Issue 4, p239 

    Presents a study regarding the safety of interrupting maintenance therapy for previous infections among patients with HIV infection. Summarizes the observational study from 358 patients; Discusses the incidences of recurrent infections.

  • Failure of prophylaxis against PCP in patients with HIV infection. Bonora, Stefano; Di Perri, Giovanni // AIDS Patient Care & STDs;Nov98, Vol. 12 Issue 11, p843 

    Cites the factors that contributed to the failure of chemoprophylaxis for Pneumocystis carinii pneumonia (PCP) in HIV-infected patients. Choice of regimen; Patient's compliance; Residual cellular immune function as complementary protective mechanism against PCP; Drug resistance and defective...

  • Continuing PCP prophylaxis? M.O.R. // Cortlandt Forum;02/25/97, Vol. 10 Issue 2, p138 

    Focuses on the effectiveness of continuing Pneumocystis carinii pneumonia (PCP) prophylaxis in HIV patients. Development of more effective retroviral therapies; Determination of PCP prophylaxis continuation in cases with improved CD4 counts.

  • Serologic Responses to Recombinant Pneumocystis jirovecii Major Surface Glycoprotein among Ugandan Patients with Respiratory Symptoms. Blount, Robert J.; Jarlsberg, Leah G.; Daly, Kieran R.; Worodria, William; Lucian Davis, J.; Cattamanchi, Adithya; Djawe, Kpandja; Andama, Alfred; Koch, Judith; Walzer, Peter D.; Huang, Laurence // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Background: Little is known about the serologic responses to Pneumocystis jirovecii major surface glycoprotein (Msg) antigen in African cohorts, or the IgM responses to Msg in HIV-positive and HIV-negative persons with respiratory symptoms. Methods: We conducted a prospective study of 550...

  • CD4 cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIV.  // BMJ: British Medical Journal (International Edition);2/12/94, Vol. 308 Issue 6926, p437 

    Evaluates the value of CD4 T cell count in the prediction of Pneumocystis carinii pneumonia in infants born to mothers with HIV infections in Europe. Proportions of children infected and uninfected with HIV; Initiation of prophylaxis with trimethoprimsulphamethaxazole following the decline in...

  • Alveolar and Blood T Lymphocyte Profiles in Pneumocystis jirovecii��"Positive Patients: Effects of HIV Status. Iriart, Xavier; Witkowski, Benoit; Cassaing, Sophie; Abbes, Sarah; Menard, Sandie; Fillaux, Judith; Valentin, Alexis; Linas, Marie-Denise; Tkaczuk, Jean; Huget, Françoise; Huynh, Anne; Hermant, Christophe; Escamilla, Roger; Kamar, Nassim; Cointault, Olivier; Lavayssiere, Laurence; Alvarez, Muriel; Blancher, Antoine; Marchou, Bruno; Magnaval, Jean-François // Journal of Infectious Diseases;8/15/2011, Vol. 204 Issue 4, p1 

    An abstract of the article "Alveolar and Blood T Lymphocyte Profiles in Pneumocystis jirovecii Positive Patients: Effects of HIV Status," by Xavier Iriart and colleagues is presented.

  • Pneumocystis carinii Pneumonia in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Immunocompromised Patients. Nuesch, Reto; Bellini, Cristina; Zimmerli, Werner // Clinical Infectious Diseases;12/1/1999, Vol. 29 Issue 6, p1519 

    Compares clinical features and changes of Pneumocytis carinii pneumonia in HIV-positive and HIV-negative immunocompromised patients. Differences in duration of symptoms, frequency of sweating, weight loss and thoracic pain; Comparison between hemoglobin levels, thrombocyte counts, C-reactive...

  • Antineoplastics.  // Reactions Weekly;12/15/2012, Issue 1432, p8 

    The article describes the case of a man who developed pneumocystis pneumonia (PCP) while under chemotherapy for advanced gastric cancer.


Read the Article


Sign out of this library

Other Topics